Biogen Idec Inc: (NASD: BIIB)

$225.18

-1.67 (-0.74%)

Volume 1,276,391

May 20 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		224.33 - 234.46
	
		52wk Low - High
		126.39 - 234.46
	
		Previous Close
		226.85
	
		Avg. Volume
		1,432,577
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		53.61 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.91
	
		PE (Forward)
		28.80
	
		Current Year Est.
		7.88
	
		Quarterly Earnings ESP 
		1.69%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/26/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            28.80
                        
                            PEG Ratio
                            1.63
                        
                            Current Year Est.
                            7.88
                        
                            Current Quarter Estimate
                            1.78
                        
                            Most Accurate Estimate
                            1.81
                        
                            Earnings ESP 
                            1.69%
                        
                            Next Earnings Report Date
                            07-23-2013
                        
                            EPS Last Year
                            7.08
                        
                            Expected Earnings Growth
                            17.66%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product, Rituxan, and our most advanced product candidate, ZEVALIN, are for use in the treatment of certain B-cell non-Hodgkin's lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis, rheumatoid arthritis and lupus).   
Full BIIB Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
BIIB Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.78	2.07	7.88	9.88
Number of Estimates	4	4	4	4
Low Estimate	1.62	1.98	7.77	9.09
High Estimate	1.96	2.13	8.03	NA
Year Ago EPS	1.82	1.90	6.53	7.88
EPS Growth	-2.06%	8.82%	20.64%	25.45%

More BIIB Estimates

Average Earnings Estimates for BIIB

EPS Growth for BIIB

Industry Analysis

Name	Symbol	Previous Close
BIOGEN IDEC INC	BIIB	226.85
AETERNA ZENTARS	AEZS	2.10
ANIKA THERAPEUT	ANIK	14.40
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALEXION PHARMA	ALXN	102.90
ALKERMES INC	ALKS	31.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Biogen's Hemophilia BLA Accepted

May 20, 2013

Isis Gets $3.5M Milestone Payment

May 14, 2013

Narrower-than-Expected Loss at Seattle Genetics

May 08, 2013

The Zacks Analyst Blog Highlights: Bayer, Biogen Idec, Conceptus, Microsoft and J. C. Penney

May 07, 2013

Bayer Discontinues Hemophilia Study

May 06, 2013

Acorda Incurs Loss, Maintains Guidance

May 06, 2013

Zacks Bull and Bear of the Day Highlights: Overstock.com, Titan Machinery, Acorda Therapeutics, Biogen Idec and Novartis

Apr 26, 2013

Acorda Initiates Study on rHIgM22

Apr 25, 2013

More BIIB Zacks Commentary

Financials

EPS TTM	7.08
Sales	5,516
Net Income	1,504
Price/Earnings	32.04
Price/Book	7.30
Price/Cash Flow	27.88
Price/Sales	9.51

More BIIB Financials

News

Leerink Swann Highlights Big Gains in Prescriptions for Biogen`s MS Treatment - Benzinga

May 20, 2013

Shares of Biogen Idec Rise to a New 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 20, 2013

Stock Investors Bid Up Shares of Biogen Idec, Up 2.4% - Financial News Network Online - Market Movers

May 20, 2013

Multiple Sclerosis and Hemophilia: This Biotech`s Just Getting Started - TheMotleyFool

May 19, 2013

IBD 50: Top 5 Medical Stocks Include Celgene, Actavis - Investors Business Daily

May 18, 2013

BRIEF: Biogen Idec awards $250G for genetics education - Mcclatchy-Tribune Information Services -- Unrestricted

May 17, 2013

Biogen Idec (BIIB) Showing Bullish Technicals But Could Break Through $232.38 Resistance - Freshbrewedmedia

May 17, 2013

Biogen Idec Foundation Awards $250,000 to East End House to Develop Genetics Education Program - Businesswire

May 16, 2013

See All News Stories on BIIB

Broker Recommendations

Current ABR	1.90
ABR (Last Week)	1.90
# of recs in ABR	21
Average Target Price	211.50
Industry Rank by ABR	91 out of 265
Rank in Industry	36 out of 155

More BIIB Broker Recommendations

Day Low - High	224.33 - 234.46
52wk Low - High	126.39 - 234.46
Previous Close	226.85
Avg. Volume	1,432,577
Industry	MED-BIOMED/GENE
Market Cap	53.61 B
Div - Yield	0.00 - 0.00
Beta	0.91
PE (Forward)	28.80
Current Year Est.	7.88
Quarterly Earnings ESP	1.69%

PE (Forward)	28.80
PEG Ratio	1.63
Current Year Est.	7.88
Current Quarter Estimate	1.78
Most Accurate Estimate	1.81
Earnings ESP	1.69%
Next Earnings Report Date	07-23-2013
EPS Last Year	7.08
Expected Earnings Growth	17.66%

Username: Password:

Remember me [?]

Biogen Idec Inc: (NASD: BIIB)

$225.18

-1.67 (-0.74%)

Volume 1,276,391

May 20 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations